Oral Medicine and Special Care Dentistry Unit, UCL Eastman Dental Institute, 256 Gray's Inn Road, WC1X 8LD London, UK.
Oral Dis. 2009 Nov;15(8):527-37. doi: 10.1111/j.1601-0825.2009.01581.x. Epub 2009 Jul 13.
Osteonecrosis of the jaw bones is a complication of bisphosphonate (BP) drug usage characterised by trans-mucosal exposure of necrotic bone, often followed by infection and pain. Osteonecrosis is observed in cancer patients on high-potency intravenous BP more frequently than in osteoporotic individuals using low-potency oral BP. The management of osteonecrosis caused by BP is often unsatisfactory and control of risk factors is considered the most effective means of prevention. Surgical manipulation and dental infection of the jawbone are the major risk factors, hence it is suggested that careful management of oral health and relevant dental procedures may decrease the risk of osteonecrosis in individuals on BP. Recommendations for dentists and oral surgeons have been suggested by different groups of clinicians but they are often controversial and there is no clear evidence for their efficacy in reducing the likelihood of osteonecrosis development. This report critically reviews current dental recommendations for individuals using BP with the aim of helping the reader to transfer them into practice as part of pragmatic and non-detrimental clinical decisions making.
颌骨骨坏死是双膦酸盐 (BP) 药物使用的一种并发症,其特征为坏死骨的跨黏膜暴露,常伴有感染和疼痛。与骨质疏松症患者使用低效能口服 BP 相比,高剂量静脉 BP 的癌症患者中更常观察到颌骨骨坏死。BP 引起的颌骨骨坏死的治疗往往不尽如人意,控制危险因素被认为是预防的最有效手段。手术操作和颌骨牙齿感染是主要的危险因素,因此建议对口腔健康和相关牙科操作进行仔细管理,可能会降低 BP 使用者发生颌骨骨坏死的风险。不同临床医生小组提出了针对牙医和口腔外科医生的建议,但它们往往存在争议,并且没有明确的证据表明它们在降低颌骨骨坏死发生的可能性方面有效。本报告批判性地审查了目前针对使用 BP 的个体的牙科建议,旨在帮助读者将其转化为实践,作为实用且无害的临床决策制定的一部分。